Eton Pharmaceuticals (ETON)
Develops and commercializes rare-disease therapies through product launches and rights agreements.
$57.50
After hours+0.35 (+0.61%)
At close$57.15(+3.33%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 69.35% | 19.82M shares | |
|---|---|---|---|
| 172 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 4.99% | 1.43M shares | |
| 9 holders · as of Aug 31, 2026 | |||
| Other | ≈ 25.66% | 7.34M shares | |
| remainder | |||
28.58M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
13F, as of Jun 30, 2026
172 holders · 19.82M shares · 58 new positions · 115 increased · 35 reduced · 6 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Opaleye Management Inc. | 2.86M | 10.01% | 0 | Aug 14, 2026 |
| Ecor1 Capital, LLC | 2.17M | 7.60% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 1.90M | 6.63% | +178.5K | Aug 7, 2026 |
| Nantahala Capital Management, LLC | 1.18M | 4.11% | 0 | Aug 19, 2026 |
| Vanguard Capital Management LLC | 976.6K | 3.42% | −17.5K | Aug 13, 2026 |
| Morgan Stanley | 768.0K | 2.69% | +290.0K | Aug 13, 2026 |
| State Street Corp | 701.8K | 2.46% | +171.6K | Aug 7, 2026 |
| Geode Capital Management, LLC | 652.3K | 2.28% | +74.6K | Aug 12, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| EcoR1 Capital, LLCincl. EcoR1 Capital Fund Qualified, L.P., Oleg Nodelman | 11.00% | 1.40M | 13G | Dec 9, 2024 |
| BlackRock, Inc. | 5.70% | 1.53M | 13G | Jul 17, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 28, 2026 | Paul V. Maierdirector | Sale · 3 lots | 50,000 | $59.07 | 59,745 |
| Aug 24, 2026 | David Krempaofficer: Chief Business Officer | Sale | 25,000 | $65.07 | 37,025 |
| Aug 20, 2026 | Sean Brynjelsendirector, officer: President & CEO | Sale · 3 lots | 91,022 | $60.70 | 961,194 |
| Aug 19, 2026 | Sean Brynjelsendirector, officer: President & CEO | Sale | 8,978 | $62.65 | 1,052,216 |
| Jul 14, 2026 | Opaleye Management Inc.10 percent owner | Sale · 2 lots | 28,315 | $37.54 | 40,000 |
| Jul 7, 2026 | Opaleye Management Inc.10 percent owner | Sale · 2 lots | 26,685 | $38.37 | 53,315 |
| Jul 2, 2026 | Opaleye Management Inc.10 percent owner | Sale · 2 lots | 90,000 | $37.39 | 60,000 |
| Jul 6, 2026 | Opaleye Management Inc.10 percent owner | Sale | 10,000 | $38.00 | 2,700,000 |
| Jun 17, 2026 | Jennifer McKie Adamsdirector | Sale | 50,000 | $32.48 | 0 |
| May 28, 2026 | Sean Brynjelsendirector, officer: President & CEO | Sale · 2 lots | 120,000 | $31.88 | 833,694 |
House and Senate disclosures
Not reported.